Literature DB >> 9230438

Molecular assessment of the potential transmissibilities of BSE and scrapie to humans.

G J Raymond1, J Hope, D A Kocisko, S A Priola, L D Raymond, A Bossers, J Ironside, R G Will, S G Chen, R B Petersen, P Gambetti, R Rubenstein, M A Smits, P T Lansbury, B Caughey.   

Abstract

More than a million cattle infected with bovine spongiform encephalopathy (BSE) may have entered the human food chain. Fears that BSE might transmit to man were raised when atypical cases of Creutzfeldt-Jakob disease (CJD), a human transmissible spongiform encephalopathy (TSE), emerged in the UK. In BSE and other TSE diseases, the conversion of the protease-sensitive host prion protein (PrP-sen) to a protease-resistant isoform (PrP-res) is an important event in pathogenesis. Biological aspects of TSE diseases are reflected in the specificities of in vitro PrP conversion reactions. Here we show that there is a correlation between in vitro conversion efficiencies and known transmissibilities of BSE, sheep scrapie and CJD. On this basis, we used an in vitro system to gauge the potential transmissibility of scrapie and BSE to humans. We found limited conversion of human PrP-sen to PrP-res driven by PrP-res associated with both scrapie (PrP[Sc]) and BSE (PrP[BSE]). The efficiencies of these heterologous conversion reactions were similar but much lower than those of relevant homologous conversions. Thus the inherent ability of these infectious agents of BSE and scrapie to affect humans following equivalent exposure may be finite but similarly low.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9230438     DOI: 10.1038/40876

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

1.  Specific binding of normal prion protein to the scrapie form via a localized domain initiates its conversion to the protease-resistant state.

Authors:  M Horiuchi; B Caughey
Journal:  EMBO J       Date:  1999-06-15       Impact factor: 11.598

2.  Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.

Authors:  C Wong; L W Xiong; M Horiuchi; L Raymond; K Wehrly; B Chesebro; B Caughey
Journal:  EMBO J       Date:  2001-02-01       Impact factor: 11.598

3.  Species-independent inhibition of abnormal prion protein (PrP) formation by a peptide containing a conserved PrP sequence.

Authors:  J Chabry; S A Priola; K Wehrly; J Nishio; J Hope; B Chesebro
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

4.  Oral infection by the bovine spongiform encephalopathy prion.

Authors:  R G Will; J W Ironside
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

5.  Methods for studying prion protein (PrP) metabolism and the formation of protease-resistant PrP in cell culture and cell-free systems. An update.

Authors:  B Caughey; G J Raymond; S A Priola; D A Kocisko; R E Race; R A Bessen; P T Lansbury; B Chesebro
Journal:  Mol Biotechnol       Date:  1999-11       Impact factor: 2.695

6.  Glycosylation influences cross-species formation of protease-resistant prion protein.

Authors:  S A Priola; V A Lawson
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

7.  Efficient conversion of normal prion protein (PrP) by abnormal hamster PrP is determined by homology at amino acid residue 155.

Authors:  S A Priola; J Chabry; K Chan
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

8.  vCJD: the epidemic that never was. New variant Creutzfeldt-Jakob disease: the critique that never was.

Authors:  R G Will; R S G Knight; H J T Ward; J W Ironside
Journal:  BMJ       Date:  2002-07-13

9.  Transmission of prions.

Authors:  C Weissmann; M Enari; P-C Klöhn; D Rossi; E Flechsig
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-14       Impact factor: 11.205

Review 10.  Getting a grip on prions: oligomers, amyloids, and pathological membrane interactions.

Authors:  Byron Caughey; Gerald S Baron; Bruce Chesebro; Martin Jeffrey
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.